The role of Positron Emission Tomography/Computed Tomography in prostate cancer

Yıl 2020, Cilt: 29 Sayı: 3, 173 - 180, 30.09.2020

Ebru Salmanoğlu

Öz

Prostate cancer is the most common cancer type in males.
Transrectal ultrasonography, computed tomography, magnetic resonance imaging,
bone scan, Positron Emission Tomography/Computed Tomography (PET/CT) is used
for staging. A variety of radiopharmaceuticals such as  Fluorine-18 Fluorodeoxyglucose, choline,
acetate are used for PET/CT imaging. It is aimed to describe the role of PET/CT
 in prostate cancer in this article.

Anahtar Kelimeler

Prostate cancer, PET/CT, PSA

Proje Numarası

Yok

Prostat kanserinde Pozitron Emisyon Tomografisi/Bilgisayarlı Tomografi’ nin rolü

Öz

Prostat kanseri erkeklerde en yaygın kanser türüdür.  Evrelemede 
transrektal ultrasonografi, bilgisayarlı tomografi, manyetik rezonans
görüntüleme, kemik sintigrafisi, Pozitron Emisyon Tomografi/Bilgisayarlı
Tomografi (PET/BT) kullanılmaktadır. PET/BT ile görüntüleme için Flor-18
Florodeoksiglukoz, kolin, asetat gibi çeşitli radyofarmasötikler
kullanılmaktadır. Bu makalede prostat
kanserinde PET/BT’ nin rolünün açıklanması amaçlanmıştır. 

Anahtar Kelimeler

Prostat kanseri, PET/BT, PSA

Destekleyen Kurum

Yok

Proje Numarası

Yok

Teşekkür

Yok

Kaynakça

• 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
• 2. Warburg O, Wind F, Negelein E. The metabolısm of tumors ın the body. J Gen Physiol. 1927;8(6):519-30.
• 3. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011;52(1):81-9.
• 4. Röthke MC, Afshar-Oromieh A, Schlemmer HP: Potential of PET/MRI for diagnosis of prostate cancer. Radiologe. 2013;53(8):676-81.
• 5. Lee ST, Lawrentschuk N, Scott AM. PET in prostate and bladder tumors. Semin Nucl Med. 2012;42(4):231-46.
• 6. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34(4):274-92.
• 7. Golubić AT, Mutvar A, Žuvić M, Huić D. The nonspecific lymph node uptake of 18F-choline in patients with prostate cancer -- a prospective observational study. Nucl Med Rev Cent East Eur. 2015;18(2):56-60.
• 8. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P. PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med. 2011;41(1):29-44.
• 9. Leiblich A, Stevens D, Sooriakumaran P. The Utility of Molecular Imaging in Prostate Cancer. Curr Urol Rep. 2016;17(3):26.
• 10. Picchio M, Mapelli P, Panebianco V, Castellucci P, Incerti E, Briganti A et al. Imaging biomarkers in prostate cancer: role of PET/CT and MRI. Eur J Nucl Med Mol Imaging. 2015;42(4):644-55.
• 11. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43(2):181-6.
• 12. Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG et al. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med. 2013;54(5):699-706.
• 13. Castellucci P, Picchio M. 11C-Choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 2013;40(Suppl 1):S36-S40.
• 14. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197-209.
• 15. Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(8):1410-7.
• 16. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486-95.
• 17. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11-20.
• 18. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52(4):637-40.
• 19. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167-72.
• 20. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528-39.
• 21. Schuhmacher J, Maier-Borst W. A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl. Int J Appl Radiat Isot. 1981;32:31–6.
• 22. Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol. 2012;2012:921674.
• 23. Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014;271(1):220-9.
• 24. Larson SM, Schöder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol. 2008;18(1):65-70.